The present invention relates to: a pharmaceutical composite capsule formulation which contains 1) an irbesartan independent unit containing irbesartan or pharmaceutically acceptable salt thereof, and 2) an HMG-CoA reductase inhibitor independent unit containing an HMG-CoA reductase inhibitor or pharmaceutically acceptable salt thereof and an alkaline additive; and a manufacturing method thereof. According to the present invention, a formulation prevents the interaction of the irbesartan and the HMG-CoA reductase inhibitor for improving stability and an elution rate, thereby improving bio-availability of drugs and drug compliance of a patient. Therefore, the formulation can be usefully used as a therapeutic agent for high blood pressure and hypercholesteremia.
展开▼
